ライフサイエンスコーパス: antihypertensive drug

1 ic blood pressure <140/90 mmHg and no use of antihypertensive drugs).

2 -dose HCTZ monotherapy is not an appropriate antihypertensive drug.

3 angiotensin system blocker and an additional antihypertensive drug.

4 d within 48 h of stroke and the last dose of antihypertensive drug.

5 that NPPA may modulate the efficacy of some antihypertensive drugs.

6 ttenuated but not eliminated by adding other antihypertensive drugs.

7 may offer new targets for the development of antihypertensive drugs.

8 hypertensive patients' response to different antihypertensive drugs.

9 s expected most (89%) are requiring multiple antihypertensive drugs.

10 e patients receiving ACE inhibitors or other antihypertensive drugs.

11 ypertensive agents compared with nonusers of antihypertensive drugs.

12 n, we selected a stratified random sample of antihypertensive drugs.

13 ure and are targets for clinically effective antihypertensive drugs.

14 s, and 25% (1,740/7,008) were not prescribed antihypertensive drugs.

15 icated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs.

16 sure >/=90 mmHg, and/or self-reported use of antihypertensive drugs.

17 lemented by the sequential addition of other antihypertensive drugs.

18 the result of control with aggressive use of antihypertensive drugs.

19 1 +/- 16 mmHg despite the use of 5.6 +/- 1.3 antihypertensive drugs.

20 7%, P=0.001) at 2 years while requiring less antihypertensive drugs.

21 sion are also associated with BP response to antihypertensive drugs.

22 mended for most patients before the start of antihypertensive drugs.

23 Trained interviewers recorded use of antihypertensive drugs.

24 d 24-h BP with HCTZ in comparison with other antihypertensive drugs.

25 right after generic commercialization for 3 antihypertensive drugs.

26 ontinue (n=379) or stop (n=384) pre-existing antihypertensive drugs.

27 ned their treatment goals with three or more antihypertensive drugs.

28 n 1992, of the 10 most frequently prescribed antihypertensive drugs, 3 were calcium antagonists, 3 we

29 Even though 67.3% of patients were on antihypertensive drugs, 46.0% of all patients had at lea

30 t calcium-channel blockers differ from other antihypertensive drugs, a meta-analysis that included al

31 or native AnCE and in complex with six known antihypertensive drugs, a novel C-domain sACE specific i

32 We assessed the association between antihypertensive drugs and cancer risk in a comprehensiv

33 Eligible patients were on >/=3 antihypertensive drugs and had a baseline systolic blood

34 nuary, 2005, for randomised trials assessing antihypertensive drugs and progression of renal disease.

35 on was found between use of other individual antihypertensive drugs and risk of psoriasis.

36 ex, year, propensity score, and use of other antihypertensive drugs and statins, DiCCB use was associ

37 Novel factors associated with VTDR include antihypertensive drugs and statins.

38 le to those seen with other major classes of antihypertensive drugs and that these falls are associat

39 fficult to control, often requiring multiple antihypertensive drugs and treatment of other risk facto

40 or long-acting calcium antagonists or other antihypertensive drugs and who were followed up for at l

41 future randomized trials comparing different antihypertensive drugs and, most important, the selectio

42 Lipid-lowering therapy, antihypertensive drugs, and anticalcific therapy have be

43 lar events and in accounting for benefits of antihypertensive drugs, and draws attention to clinical

44 k of vascular events and for the benefits of antihypertensive drugs, and this notion has come to unde

45 disease, diabetes, lung disease, and use of antihypertensive drugs; and other types of physical acti

46 In addition to inadequate prescription of antihypertensive drugs, another confounder is poor diagn

47 ates for beta3- and beta2-receptor agonists, antihypertensive drugs, antiviral agents, melatonin rece

48 Most comparisons of antihypertensive drugs are undertaken in parallel groups

49 To achieve therapy goals, multiple antihypertensive drugs are usually needed.

50 m antagonists are inferior to other types of antihypertensive drugs as first-line agents in reducing

51 ent submitted to medical therapy was free of antihypertensive drugs at 12 months.

52 HTN trial, the prevalence of nonadherence to antihypertensive drugs at 6 months was high ( approximat

53 lone, and 29,096 infants with no exposure to antihypertensive drugs at any time during gestation.

54 atrial fibrillation or taking rate-limiting antihypertensive drugs at baseline were excluded.

55 Lipid-lowering, anticoagulant, and antihypertensive drugs can prevent strokes, but may be u

56 tive was to quantify the association between antihypertensive drug class and adherence in clinical se

57 ing indications for the initial use of other antihypertensive drug classes (angiotensin-converting en

58 In adults with hypertension, how do various antihypertensive drug classes differ in their benefits a

59 etic therapy but not present for other major antihypertensive drug classes, and did not differ substa

60 ring of blood pressure and self-titration of antihypertensive drugs, combined with telemonitoring of

61 ent parameters as indexes to predict how the antihypertensive drugs could influence muscle function.

62 The exclusion of women on antihypertensive drugs did not alter the results.

63 ly and non-adjustment for lipid-lowering and antihypertensive drugs did not introduce major biases in

64 Continuation of antihypertensive drugs did not reduce 2-week death or de

65 ecline in pCBF, whereas patients using other antihypertensive drugs did show a decline in pCBF.

66 Antihypertensive drugs differ in their effects on left a

67 stic sensitivity analyses explored ranges of antihypertensive drug effectiveness and costs, monitorin

68 Spironolactone is an effective antihypertensive drug, especially for patients with resi

69 have an influence: 41.7% of patients taking antihypertensive drugs experienced a severe reaction com

70 ts, no dose reductions, and no more than two antihypertensive drugs for 2 consecutive weeks were stra

71 tion to either continue or stop pre-existing antihypertensive drugs for 2 weeks.

72 nce of baseline comorbidities, and trials of antihypertensive drugs for indications other than hypert

73 The fixed-dose combination of any two antihypertensive drugs from different drug classes is ty

74 ic strategy in which the clinically licensed antihypertensive drug guanabenz (Wytensin) activates a s

75 patients' age in regression analysis, taking antihypertensive drugs had no effect on symptom severity

76 The risk of cancer from antihypertensive drugs has been much debated, with a rec

77 In contrast, few of the antihypertensive drugs have been found to be carcinogeni

78 Antihypertensive drugs have disparate effects on LV mass

79 Randomization to 1 of 6 antihypertensive drugs: hydrochlorothiazide, atenolol, c

80 spite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant

81 hageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the

82 ry modification, exercise, antioxidants, and antihypertensive drugs improve endothelial dysfunction i

83 Labetalol and lisinopril are effective antihypertensive drugs in acute stroke that do not incre

84 s have explored the renal effects of various antihypertensive drugs in animal models and humans, rece

85 afety of continuing or stopping pre-existing antihypertensive drugs in patients who had recently had

86 Losartan is exceptional amongst antihypertensive drugs in possessing mild uricosuric pro

87 ting enzyme inhibitors are superior to other antihypertensive drugs in reducing the risk for acute my

88 Unexplained differences between classes of antihypertensive drugs in their effectiveness in prevent

89 ossover rotation of the four main classes of antihypertensive drugs, in untreated young hypertensive

90 0 mm Hg, despite adherence to >/=3 full-dose antihypertensive drugs including a diuretic agent or >/=

91 iate pharmacologic treatment with at least 3 antihypertensive drugs, including a diuretic agent.

92 ast 160 mm Hg and were taking at least three antihypertensive drugs, including a diuretic, at the opt

93 re (BP) >/=140/90 mm Hg (with at least three antihypertensive drugs, including a diuretic, in adequat

94 e been demonstrated by quickly accessing the antihypertensive drug irbesartan (2).

95 iption of lipid-lowering, anticoagulant, and antihypertensive drugs is important to reduce the incide

96 ACE (both in the presence and absence of the antihypertensive drug lisinopril) in order to aid the un

97 All antihypertensive drugs lower blood pressure (by definiti

98 Antihypertensive drugs may differ in their ability to re

99 ese preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity an

100 gain after smoking cessation and the use of antihypertensive drugs may have counterbalanced the bene

101 These observations suggest not only that antihypertensive drugs may have important mechanisms of

102 The efficacy of antihypertensive drugs newer than diuretics and beta-blo

103 tigational drug was compared with the common antihypertensive drug nifedipine, which has 4.5-fold sel

104 Patients were treated with 5.1 +/- 1.4 antihypertensive drugs on average.

105 The effect of antihypertensive drugs on cardiovascular events in patie

106 50% of patients with acute stroke are taking antihypertensive drugs on hospital admission.

107 The effect of different classes of antihypertensive drugs on incident diabetes mellitus is

108 the effects of calcium antagonists and other antihypertensive drugs on major cardiovascular events.

109 re can account for differences in effects of antihypertensive drugs on risk of stroke independently o

110 reached, have been neglected, and effects of antihypertensive drugs on such measures are largely unkn

111 ly, we review the known effects of available antihypertensive drugs on the arterial wall and indicate

112 Hg) who were randomly assigned to an active (antihypertensive drug or more intensive regimen) or cont

113 stolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease to medi

114 ng doxazosin, treatment assignment to either antihypertensive drugs or pravastatin versus usual care

115 VTDR, we also found novel associations with antihypertensive drugs (OR: 0.18; 95% CI: 0.06-0.61) and

116 Among the 3648 patients receiving antihypertensive drugs other than ACE inhibitors (calciu

117 Therefore, in addition to their use as antihypertensive drugs, our results suggest that thiazid

118 (p=0.002), and -17.9 cm/s in never users of antihypertensive drugs (p=0.001).

119 /s in continuous/intermittent users of other antihypertensive drugs (p=0.002), and -17.9 cm/s in neve

120 kg in continuous/intermittent users of other antihypertensive drugs (p=0.016) and with -3.9 kg in tho

121 al outcomes) based on blood pressure, use of antihypertensive drugs, plasma potassium and aldosterone

122 We found that the antihypertensive drug Prazosin inhibits endocytic sortin

123 lacebo group received placebo and any active antihypertensive drugs prescribed by patient's private p

124 and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and p

125 The SHEP antihypertensive drug regimen lowered BP of both diabeti

126 Patients' adherence to antihypertensive drug regimens is a complex but importan

127 Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic,

128 lood pressure, adding meaningful efficacy to antihypertensive drug regimens.

129 re, understanding the therapeutic effects of antihypertensive drugs related to apoptosis may identify

130 encing data to identify molecular markers of antihypertensive drug response.

131 ly and non-adjustment for lipid-lowering and antihypertensive drugs resulted in marginal changes in O

132 Taking antihypertensive drugs seemed to have an influence: 41.7

133 rugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hy

134 noic acid and Idoxuridine and reduced by the antihypertensive drug Spironolactone.

135 -related deaths with any individual class of antihypertensive drugs studied.

136 vailable data on the renal outcomes of other antihypertensive drugs such as calcium antagonists have

137 mm Hg, [-9.47 to -0.79]) as their additional antihypertensive drug than in those receiving a thiazide

138 nest treatment, minoxidil, was originally an antihypertensive drug that promoted unwanted hair.

139 by amlodipine and verapamil, are widely used antihypertensive drugs that also have antiinflammatory a

140 such as verapamil are a widely used class of antihypertensive drugs that block L-type calcium channel

141 nd was added to a mean of 2.0 (SD 0.3) other antihypertensive drugs; the mean starting and final dose

142 of age who were free of CHD and were not on antihypertensive drug therapy at baseline.

143 In this population, specific antihypertensive drug therapy had little impact on the r

144 Stepped-care antihypertensive drug therapy, in which the step 1 drug

145 After excluding subjects receiving antihypertensive drug therapy, up to 30 years of data on

146 pressure can be controlled through existing antihypertensive drug therapy.

147 h no clinical evidence of CHD and not taking antihypertensive drug therapy.

148 and angiotensin blockers as cornerstones of antihypertensive drug therapy.

149 ion comprised withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825-853

150 pants and for men receiving or not receiving antihypertensive drug treatment and were controlled for

151 In this study, antihypertensive drug treatment reduced the incidence of

152 mized clinical trial testing the efficacy of antihypertensive drug treatment to reduce the risk of st

153 m Hg or DBP >/=90 mm Hg or the initiation of antihypertensive drug treatment, occurred in 228 men (22

154 our groups according to type and duration of antihypertensive drug treatment.

155 of a higher treatment rate and more intense antihypertensive drug treatment.

156 rdiovascular history, and lipid-lowering and antihypertensive drug treatments.

157 = 6); or SP combined with nonspecific triple antihypertensive drugs (TRX; reserpine, hydralazine, and

158 2 mm Hg, despite medication with 5.4 +/- 1.4 antihypertensive drugs) underwent RDN.

159 with randomisation stratified by additional antihypertensive drug use and insulin use at baseline, i

160 Multiple antihypertensive drug use increased from 29.1% to 35.8%

161 nd similar diuretics, and the association of antihypertensive drug use with new-onset diabetes and it

162 Advancing age, male sex, antihypertensive drug use, higher body mass index, previ

163 Hypertension was defined as predonation antihypertensive drug use.

164 We aimed at evaluating racial differences in antihypertensive drug utilization patterns and blood pre

165 90] mm Hg; p > 0.01) but the requirement for antihypertensive drugs was unchanged.

166 ribed when lipid-lowering, anticoagulant, or antihypertensive drugs were clinically indicated but wer

167 Patients aged over 18 years who were taking antihypertensive drugs were enrolled within 48 h of stro

168 igible for lipid-lowering, anticoagulant, or antihypertensive drugs were not prescribed them prior to

169 HI was 40.4 (SD, 18.9) and an average of 3.8 antihypertensive drugs were taken per patient.

170 Other antihypertensive drugs, while not tested in large trials

171 Multiple antihypertensive drugs will be required in the vast majo

172 tudinal association of hypertension, BP, and antihypertensive drugs with change in parenchymal cerebr

173 The association of antihypertensive drugs with incident diabetes is therefo

174 HCTZ is the most commonly prescribed antihypertensive drug worldwide.

175 arisons of ACE inhibitors or ARBs with other antihypertensive drugs yielded a relative risk of 0.71 (